Melbourne, Australia;
05 October 2021 – OBM Enters R&D Agreement with Centre for Eye Research Australia (“CERA”)
Melbourne, Australia; 11 June 2021 – Key Chinese Patent covering OBM-1701 Granted
June 11, 2021Melbourne, Australia; 22 February 2022 – Research Data Which Covers OBM’s OBM-1701 for the Treatment of wet-AMD Has Been Published on a Prominent Peer-reviewed Journal
February 22, 2022Oculus Biomed Limited (“OBM”) is pleased to announce that it has entered an Agreement with Centre for Eye Research Australia (“CERA”), in Melbourne, Victoria State, Australia. Established in 1996, CERA ranks in the world’s top 5 institution for ophthalmology research, CERA is an international leader in eye research and Australia’s only designated World Health Organization (“WHO”) Collaborating Centre for the Prevention of Blindness, working to reduce the global burden of vision impairment. A group of medical research experts, led by the Professor Mark Daniell, Professor Greg Dusting and Dr. Karl Brown, will conduct commissioned research on OBM’s Corneal Scaffold Endothelialisation Project for improving the successful rates by keratoplasty.
